CAN-2409 improved disease-free survival by 30% versus placebo in a 745-patient Phase 3 trial in intermediate-to-high-risk localized prostate cancer...

Updated Phase 1 data from Elicio’s AMPLIFY-201 program reported a 16.3-month median recurrence-free survival and 28.9-month median overall survival...

The patient drove two hours each way for the trial, which her oncologist and she believed was her best...

CLINUVEL has advanced a portfolio of sustained‑release liquid depot formulations for peptides into preclinical testing, targeting predictable release kinetics...

At the Veeva R&D and Quality Summit in Boston, we interviewed Dr. Christina Brennan, Senior Vice President of Clinical...

ADvantage Therapeutics secured a $2.5 million Phase II SBIR grant from the National Institute on Aging to advance AD04,...

Updated overall survival and safety data from a 34‑patient, first‑line pancreatic cancer cohort treated with atebimetinib plus modified gemcitabine/nab‑paclitaxel...

In a randomized, double-blind, sham-controlled midpoint cohort of REMAIN-1 (N=45), Revita produced an additional 2.5% total body weight loss...

ReNu’s second Phase 3 randomized trial in symptomatic knee osteoarthritis missed its primary endpoint, showing a 0.5-point advantage over...

Cidara has begun dosing in ANCHOR, a global Phase 3 trial of CD388, a single 450 mg subcutaneous dose...